Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Mono Pharmacare Limited is engaged in the marketing and distribution of pharmaceutical products, operating since 1994. Their portfolio includes antibiotics, antifungals, skincare, and cardiac drugs, manufactured through contract partners.
The company transitioned from a partnership to a public limited entity in October 2022, indicating an organized structural evolution for better market access and capital acquisition.
In August 2023, Mono Pharmacare launched an IPO raising Rs 14.84 crore, suggesting strategic financial planning to fuel future growth and opportunities.
The company has actively acquired related entities, consolidating operational strengths and expanding market coverage in the industry.
Mono Pharmacare is led by Promoters Panilam and Supal Lakhatariya, who have been strategically acquiring related firms to bolster the company's value proposition.
Pharmaceuticals & Biotechnology
Pharmaceuticals
21 Cr
Low Risk
24.8
34.3
0.3
0.7
27.50
9.45
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Mono Pharmacare Ltd (MONOPHARMA) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Mono Pharmacare Limited is engaged in the marketing and distribution of pharmaceutical products, operating since 1994. Their portfolio includes antibiotics, antifungals, skincare, and cardiac drugs, manufactured through contract partners. The company transitioned from a partnership to a public limited entity in October 2022, indicating an organized structural evolution for better market access and capital acquisition. In August 2023, Mono Pharmacare launched an IPO raising Rs 14.84 crore, suggesting strategic financial planning to fuel future growth and opportunities. The company has actively acquired related entities, consolidating operational strengths and expanding market coverage in the industry. Mono Pharmacare is led by Promoters Panilam and Supal Lakhatariya, who have been strategically acquiring related firms to bolster the company's value proposition.
Over the past 52 weeks, Mono Pharmacare Ltd has traded between a low of ₹9.45 and a high of ₹27.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Mono Pharmacare Ltd has a market capitalization of approximately 20.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Mono Pharmacare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 20.58 Cr, Mono Pharmacare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Mono Pharmacare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Mono Pharmacare Ltd is 24.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
46
Bullish
0
Bearish
0
Neutral
32
Bullish
0
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
74.70 | 22 Cr | 28.77 | 1.94 | 0.00 | 6.73 | 9.78 | 6.19 | ||
59.32 | 22 Cr | -5.35 | 0.00 | 0.00 | 67.65 | -85.76 | -14.80 | ||
40.00 | 22 Cr | 14.58 | 0.94 | 0.00 | 6.49 | 7.62 | 0.44 | ||
23.20 | 22 Cr | 8.82 | 1.15 | 0.00 | 13.09 | 13.74 | 4.84 | ||
8.26 | 21 Cr | -0.89 | 2.42 | 0.00 | -117.84 | -25.84 | -37.84 | ||
11.65 | 21 Cr | 24.80 | 0.66 | 0.00 | 2.67 | 6.38 | 0.70 | ||
35.00 | 20 Cr | 34.98 | 1.53 | 0.00 | 4.23 | 5.80 | 2.73 | ||
| Median: 7 Co. | — | 35.00 | 22 Cr | 14.58 | 1.15 | 0.00 | 6.49 | 6.38 | 0.70 |
Record Date Notice
Mono Pharmacare has fixed 23‑Jun‑2026 as the record date to determine shareholders eligible for remote e‑voting for the Extraordinary General Meeting scheduled on 30‑Jun‑2026.
EGM Notice
Mono Pharmacare will hold an Extraordinary General Meeting on 30 June 2026 at 11:00 AM (physical & VC/OAVM) to appoint M/s R K Mergu & Co. as statutory auditor to fill a casual vacancy and to regularize Ms. Nirmala Ranawat as an independent director for five years.
